Gut bacteria boosts cancer treatment? new trial tests Probio-M9 in rectal cancer
NCT ID NCT07458529
First seen Mar 14, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tests whether adding a probiotic called Probio-M9 to standard chemoradiation and immunotherapy (tislelizumab) can help shrink rectal tumors before surgery. About 50 adults with locally advanced rectal cancer will be randomly assigned to receive the probiotic or a placebo alongside treatment. The main goal is to see if the probiotic increases the chance of no cancer remaining after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seventh Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.